MedTrace Logo

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

NCT03735446 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-06-12

No results posted yet for this study

Summary

This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).

The drugs involved in this study are:

* Prexasertib (LY2606368)
* Mitoxantrone
* Etoposide
* Cytarabine

Conditions

Interventions

DRUG

Prexasertib

Checkpoint kinase 1 (CHK1) inhibitor

DRUG

Mitoxantrone

Standard chemotherapy (topoisomerase inhibitor)

DRUG

Etoposide

Standard chemotherapy (topoisomerase II inhibitor)

DRUG

Cytarabine

Standard chemotherapy (anti-metabolite)

Sponsors & Collaborators

Principal Investigators

  • Eric S Winer, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-18
Primary Completion
2019-03-29
Completion
2019-03-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03735446 on ClinicalTrials.gov